Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN24493 in Graves' Disease
NCT07861152Phase 1Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2026
- Primary completion
- Jan 2030
01
Overview
Phase 1 trial of REGN24493 in Graves' disease (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events at 68 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
REGN24493
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT07861152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07861152.